Using two distinct models of castration sensitive advanced prostate cancer, we identified tumor-specific differences in intratumoral androgen levels and expression of ARFL and ARSV which associate with response and resistance to pre-receptor suppression of AR ligands. This evidence concerns the gene AR and prostate carcinoma.